In the North American VIEW 1 study, 96% of patients receiving VEGF Trap-Eye 0.5mg monthly, 95% receiving 2mg monthly, and 95% receiving 2mg every two months achieved maintenance of vision compared to 94% of patients receiving ranibizumab 0.5mg dosed every month. In the international VIEW 2 study, 96% of patients receiving VEGF Trap-Eye 0.5mg monthly, 96% receiving 2mg monthly, and 96% receiving 2mg every two months achieved maintenance of vision compared to 94% of patients receiving ranibizumab 0.5mg dosed every month.
In the VIEW 1 study, patients receiving VEGF Trap-Eye 2mg monthly achieved a statistically significant greater mean improvement in visual acuity at week 52 versus baseline (secondary endpoint), compared to ranibizumab 0.5mg monthly. All other dose groups of VEGF Trap-Eye in the VIEW 1 and VIEW 2 studies were not statistically different from ranibizumab in this secondary endpoint. Additionally, a generally favorable safety profile was observed for both VEGF Trap-Eye and ranibizumab.